All Archives - Gilde Healthcare

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy

1 April 2025

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy

1 April 2025

Gilde Healthcare announces successful sale of health-it software company Performation to Enovation, part of Legrand

Exit confirms Gilde Healthcare's investment strategy of building market-leading healthcare companies that deliver better care at lower cost Under ownership of Gilde Healthcare’s private equity fund, Performation has evolved into...

13 February 2025

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy

1 April 2025

Filter & search

Search:

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with...

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its board chair position. Philip Astley-Sparke has been appointed as new chair of the board of directors, reflecting...

April 1, 2025

Gilde Healthcare company SpliceBio announces first patient dosed in Phase 1/2 ASTRA study ...

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused...

March 13, 2025

Gilde Healthcare participates in $65 Million financing of Microtransponder to enhance Vivi...

MicroTransponder®, Inc, today announces a $65 million Series F financing round. MicroTransponder is a fast growing commercial stage stroke company with the FDA-approved Vivistim® Paired VNS™ System. Gilde Healthcare joins the round as new investor, together with Longitude Capital. Existing investors include US Venture Partners (USVP), Osage...

March 12, 2025

Gilde Healthcare Company Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive ...

Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, today announces the appointment of Haseeb Ahmad as its Chief Executive Officer and member of the Board of Directors effective immediately. Haseeb has been appointed to steer Purespring through a critical phase of development...

March 12, 2025

Gilde Healthcare company Shoulder Innovations Announces Closing of $40 Million Series E Eq...

Shoulder Innovations, a leader in shoulder replacement technology, today announced the closing of a $40 million Series E equity financing round. The financing was led by existing investor U.S. Venture Partners (USVP), with support from additional existing investors including Gilde Healthcare Partners, Gilmartin Capital, and Aperture Venture...

March 10, 2025

Gilde Healthcare announces successful sale of health-it software company Performation to E...

Exit confirms Gilde Healthcare’s investment strategy of building market-leading healthcare companies that deliver better care at lower cost Under ownership of Gilde Healthcare’s private equity fund, Performation has evolved into a leading European SaaS healthcare platform through seven strategic acquisitions and product innovations Revenue more than doubled...

February 13, 2025

Gilde Healthcare company NIZO participates in national consortium investing in precision f...

The Netherlands is strengthening its position as a global leader in cellular agriculture with the launch of two independent, open-access scale-up facilities. These facilities, developed in a collaboration between NIZO Food Research, Cultivate at Scale (CaS), Cellular Agriculture Netherlands Foundation (CAN), Biotechnology Fermentation Factory Ede (BFF), Mosa...

February 4, 2025

Gilde Healthcare company GT Medical Technologies raises $37 million in to advance GammaTil...

GT Medical Technologies, Inc. (GT MedTech), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced the company has completed a $37 million first close of a Series D financing round. The financing was led by Evidity Health...

January 17, 2025

Alleviant Medical Secures $90 Million Financing to Expand Interventional Heart Failure Piv...

Alleviant Medical, Inc., a privately held medical device company developing a no-implant atrial shunt for heart failure, today announced a $90 million financing to fund its second pivotal trial. Led by Gilde Healthcare, the round also adds Omega Funds and includes participation from existing shareholders S3 Ventures, RiverVest...

January 14, 2025

These were all articles

891aaa94ab